Status
Conditions
Treatments
About
Glaucoma is the second leading cause of blindness worldwide. Literature shows increasing evidence that dysfunction of ocular microcirculation in the optic nerve influences the progression of glaucoma. It has been shown that flicker light-induced vasodilatation of retinal veins is diminished in patients with glaucoma. Also previous studies indicate that the blood flow autoregulation is impaired in patients with glaucoma. Therefor the ocular perfusion pressure can not be maintained stable during changes of the systemic arterial blood pressure. Laser speckle flowgraphy (LSFG) represents a non-invasive method to quantify ocular perfusion also at the ONH. LSFG enables noninvasive quantification of microcirculation of the optic disc in Japanese glaucoma patients.
Study Objectives:
To assess the changes in LSFG parameters in patients with normal tension glaucoma, compared to healthy subjects during flicker light stimulation and isometric exercises.
Enrollment
Sex
Volunteers
Inclusion and exclusion criteria
Study population: patients with normal tension glaucoma
Control group
Exclusion Criteria:
a) Study population: patients with normal tension glaucoma
History of ocular or systemic disease causing optic nerve damage
History of IOP greater than 21 mm Hg (corrected by CCT)
Participation in a clinical trial in the 3 weeks preceding the study
Ocular surgery (including intravitreal injection) during the 3 months preceding the study
Ametropia > 6 Dpt
Smoking
pre- or perimenopausal women
Relevant ophthalmic diseases/conditions that could interfere with LSFG measurements (e.g. optic nerve head drusen, tilted disc, etc.)
Opacities of the cornea (e.g. corneal scars, corneal oedema), the lens (e.g. LOCS-II grading > 2, posterior capsule opacification) or the vitreous (e.g. vitreous haemorrhage, asteroid hyalosis)
Patients who are not able to cooperate or with insufficient ability to fixate (tremor, nystagmus)
Blood donation in the 3 weeks preceding the study
Symptoms of a clinically relevant illness in the 3 weeks before the first study day
Ocular infection or clinically significant inflammation
Pregnancy, planned pregnancy or lactating
b) Control group
Abnormal RNFL
Visual field defects
Participation in a clinical trial in the 3 weeks preceding the study
Ocular surgery (including intravitreal injection) during the 3 months preceding the study
Ametropia > 6 Dpt
Smoking
Relevant ophthalmic diseases/conditions that could interfere with LSFG measurements (e.g. optic nerve head drusen, tilted disc, etc.)
Opacities of the cornea (e.g. corneal scars, corneal oedema), the lens (e.g. LOCS-II grading > 2, posterior capsule opacification) or the vitreous (e.g. vitreous haemorrhage, asteroid hyalosis)
Patients who are not able to cooperate or with insufficient ability to fixate (tremor, nystagmus)
Blood donation in the 3 weeks preceding the study
Symptoms of a clinically relevant illness in the 3 weeks before the first study day
Ocular infection or clinically significant inflammation
Pregnancy, planned pregnancy or lactating
Primary purpose
Allocation
Interventional model
Masking
24 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal